Delivery of therapeutic agent
AssigneeVL27, Inc.
InventorsJan LÖTVALL, Jonas Andrej NILSSON
Life of this patent
Estimating the term…
Abstract
A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
Claims25
A method of producing nanovesicles comprising an inhibitor oligonucleotide to an oncogene or a proto-oncogene or the gene product thereof, said method comprising
- a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell;
- b) maintaining the cell under conditions allowing the cell to express said inhibitor oligonucleotide;
- and
- c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell.
A method according to any one of the preceding claims, wherein said oligonucleotide is RNA, preferably an RNAi molecule.
A method according to any one of the preceding claims, wherein said cell expresses a targeting molecule on the cell surface.
A method according to any one of the preceding claims, wherein the method comprises, prior to step a) or simultaneously with step a), introducing a DNA sequence coding for a targeting molecule to be expressed on the cell surface.
A method according to any one of the preceding claims, wherein the cell is a human cell.
A method according to any one of the preceding claims, wherein the cell is transfected or transduced with a construct comprising the N-Myc or L-Myc genes and overexpresses N-Myc or L-Myc.
A method according to any one of the preceding claims, wherein step a) comprises introducing a genetic construct comprising said DNA sequence coding for an oligonucleotide capable of inhibiting human c-Myc, operatively linked to an inducible promoter, and step b) comprises inducing expression by activation of said inducible promoter.
A method according to any one of the preceding claims, performed in vitro or ex vivo.
An isolated nanovesicle produced by the method according to any one of the preceding claims.
An isolated nanovesicle comprising an inhibitor oligonucleotide to a human oncogenic or proto-oncogenic transcription factor.
A human cell transfected or transduced with a genetic construct comprising a gene whose gene product functionally replaces a human oncogenic or proto-oncogenic transcription factor naturally expressed by said human cell, wherein the cell further contains a DNA sequence encoding an oligonucleotide capable of inhibiting said human oncogenic or proto-oncogenic transcription factor.
A human cell transduced or transfected with a DNA sequence coding for an inhibitor oligonucleotide to a human oncogene or proto-oncogene, preferably a human oncogenic or proto-oncogenic transcription factor, wherein said DNA sequence is operably linked to an inducible promoter.
Dependencies are inferred from the claim text.